Zai Lab Limited (NASDAQ:ZLAB) CFO Sells $13,241.15 in Stock

Zai Lab Limited (NASDAQ:ZLAB) CFO Yajing Chen sold 845 shares of the firm’s stock in a transaction that occurred on Thursday, April 4th. The stock was sold at an average price of $15.67, for a total transaction of $13,241.15. Following the sale, the chief financial officer now owns 9,618 shares of the company’s stock, valued at $150,714.06. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Yajing Chen also recently made the following trade(s):

• On Tuesday, April 2nd, Yajing Chen sold 519 shares of Zai Lab stock. The stock was sold at an average price of $16.15, for a total transaction of $8,381.85.

Zai Lab Stock Performance

Zai Lab stock opened at $15.52 on Monday. The firm’s fifty day simple moving average is $19.15 and its 200-day simple moving average is $23.52. Zai Lab Limited has a 1-year low of $15.24 and a 1-year high of $40.42.

Zai Lab (NASDAQ:ZLAB) last released its quarterly earnings results on Tuesday, February 27th. The company reported ($0.98) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.87) by ($0.11). The business had revenue of $65.83 million for the quarter, compared to the consensus estimate of $70.41 million. Zai Lab had a negative net margin of 125.46% and a negative return on equity of 37.07%. On average, research analysts predict that Zai Lab Limited will post -3.1 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors have recently bought and sold shares of the company. UBS Group AG raised its holdings in Zai Lab by 312.4% in the 3rd quarter. UBS Group AG now owns 288,981 shares of the company’s stock worth $7,025,000 after acquiring an additional 218,907 shares during the period. China Universal Asset Management Co. Ltd. grew its position in Zai Lab by 323.2% in the 4th quarter. China Universal Asset Management Co. Ltd. now owns 5,802 shares of the company’s stock worth $159,000 after purchasing an additional 4,431 shares during the last quarter. Bamco Inc. NY grew its position in Zai Lab by 4.5% in the 3rd quarter. Bamco Inc. NY now owns 1,579,349 shares of the company’s stock worth $38,394,000 after purchasing an additional 67,288 shares during the last quarter. Nomura Holdings Inc. acquired a new stake in shares of Zai Lab during the 3rd quarter valued at about $1,169,000. Finally, XY Capital Ltd acquired a new stake in shares of Zai Lab during the 3rd quarter valued at about $3,397,000. Institutional investors own 41.65% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently weighed in on ZLAB. Cantor Fitzgerald restated an “overweight” rating on shares of Zai Lab in a report on Friday, January 12th. Citigroup decreased their price objective on shares of Zai Lab from $123.00 to $66.00 and set a “buy” rating for the company in a research note on Thursday, February 29th. Finally, Morgan Stanley began coverage on shares of Zai Lab in a research note on Thursday, December 14th. They set an “overweight” rating and a $47.50 target price for the company. Five equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $64.22.

About Zai Lab

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.